Newsroom
Follow us as we passionately pursue our goal of improving life for those with cancer.
Get the latest
-
AVEO Pharmaceuticals, Inc. Announces Timing for Third Quarter 2010 Financial Results, Webcast and Conference Call
Download PDF CAMBRIDGE, Mass., Oct 21, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that financial results for the company’s third quarter ended September 30, 2010 will be released before the market opens on Thursday, November 4, 2010. The AVEO management…
-
AVEO Pharmaceuticals’ Tivozanib Clinical Data Featured at ESMO
Download PDF CAMBRIDGE, Mass. & MILAN, Oct 11, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC) were presented at the 35th European…
-
AVEO Pharmaceuticals’ Tivozanib Featured at Ninth International Kidney Cancer Symposium
Download PDF Tivozanib Clinical Data and Pipeline Overview Presented CAMBRIDGE, Mass., Oct 01, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that previously reported results from its Phase 2 study evaluating tivozanib for the treatment of advanced renal cell carcinoma (RCC)…
-
AVEO Pharmaceuticals Regains Worldwide Rights to Develop and Commercialize Anti-HGF Antibody Candidate AV-299
Download PDF CAMBRIDGE, Mass., Sep 30, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that AVEO has regained worldwide rights from Merck (through its subsidiary, Schering Corporation) to develop and commercialize AV-299 (also known as SCH 900105), its anti-hepatocyte growth factor…
-
AVEO Pharmaceuticals, Inc. to Present at Upcoming Oncology Medical Meetings and Investment Conference
Download PDF CAMBRIDGE, Mass., Sep 28, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company will have a presence at two upcoming oncology medical meetings and Citi’s 5th Annual Biotech Day investment conference. Data from AVEO’s tivozanib clinical development program…
-
AVEO Pharmaceuticals, Inc. Appoints Michael P. Bailey to the Newly Created Position of Chief Commercial Officer
Download PDF Company Enhances Leadership Team and Prepares for Forward Integration CAMBRIDGE, Mass., Sep 13, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the appointment of Michael P. Bailey to the newly created role of chief commercial officer, as well as…
-
AVEO Pharmaceuticals, Inc. to Present at Several Upcoming Investment Conferences
Download PDF CAMBRIDGE, Mass., Sep 02, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company’s management will present at several upcoming investment conferences. Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the following events: David…
-
AVEO Achieves Enrollment Target Ahead of Schedule for Pivotal Phase 3 Trial of Tivozanib in Patients with Advanced Renal Cell Carcinoma
Download PDF CAMBRIDGE, Mass. Aug 12, 2010 — (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has achieved its enrollment target for TIVO-1, its global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in patients with…
Follow us on social media
Media inquiries
For media inquiries, please contact:
John F. Kouten, CEO
JFK Communications, Inc.
jfkouten@jfkhealth.com
Direct: 609-241-7352
Download our media kit:
Meet our leadership team
The AVEO oncology management team comprises executives with years of oncology and pharmaceutical industry experience and expertise with a proven track record for success in bringing important new therapies to patients.